New hope for myeloma: targeted drug combo takes on Tough-to-Treat cancer
NCT ID NCT06868667
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new combination of drugs—belantamab mafodotin plus bortezomib and dexamethasone—works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people in Japan with multiple myeloma that has come back or stopped responding to treatment. About 24 participants will be randomly assigned to one of the two combos. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted antibody-drug conjugate) combined with bortezomib and dexamethasone
What this could lead to
If this works, it could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to earlier therapy.
What could go wrong
This is a small, early-phase study in Japan only, so results may not apply broadly. The experimental combo may not prove better than the standard daratumumab combo, and side effects like eye problems are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Aomori, Japan
-
GSK Investigational Site
Fukuoka, Japan
-
GSK Investigational Site
Himeji, Japan
-
GSK Investigational Site
Kamakura, Japan
-
GSK Investigational Site
Kitakyushu, Japan
-
GSK Investigational Site
Kochi, Japan
-
GSK Investigational Site
Matsuyama, Japan
-
GSK Investigational Site
Nagoya, Japan
-
GSK Investigational Site
Okayama, Japan
-
GSK Investigational Site
Osaka, Japan
-
GSK Investigational Site
Ōgaki, Japan
-
GSK Investigational Site
Shibukawa, Japan
-
GSK Investigational Site
Sunto-gun, Japan
-
GSK Investigational Site
Suwa, Japan
-
GSK Investigational Site
Toyohashi, Japan
-
GSK Investigational Site
Yokohama, Japan